-
April 25, 2013
AstraZeneca has posted a 13% decline in first-quarter revenues to $6.39 billion, due to the loss of exclusivity on key brands, but analysts believe things are starting to improve at the Anglo-Swedish drugmaker
Full story
-
July 18, 2012
Drug giant AstraZeneca has announced plans to carry out a clinical trial pitting its blood thinner Brilinta against clopidogrel in patients with peripheral artery disease (PAD).
Full story
-
May 18, 2012
The US market for Sanofi/Bristol-Myers Squibb's Plavix has been blown wide open after regulators across the Atlantic gave the green light to copycat versions of the companies' mega-blockbuster bloodthinner
Full story
-
April 26, 2012
As it posted disappointing sales and earnings for the first quarter, AstraZeneca has announced that chief executive David Brennan is to retire, amid pressure from disgruntled shareholders
Full story
-
February 23, 2012
AstraZeneca's bid to push up market share of its new antiplatelet drug Brilinta has been helped by a recommendation from the influential American College of Chest Physicians
Full story
-
February 06, 2012
Somewhat lost amid talk of its major restructuring plans, AstraZeneca actually posted a reasonably healthy set of financials for the fourth quarter
Full story
-
October 27, 2011
In final guidance, NICE has recommended the use of AstraZeneca's "clotbuster" Brilique, in combination with aspirin and for up to 12 months, as an option to treat adults with acute coronary syndromes.
Full story
-
August 04, 2011
The approval in July of AstraZeneca's Brilinta (ticagrelor) brings to 21 the total of new drugs approved by the US FDA in 2011 so far, which is equal to the total of all new drugs it approved last year, says a new report.
Full story
-
July 20, 2011
AstraZeneca is celebrating after finally getting the green light from US regulators for its bloodthinner Brilinta, a drug that is widely-viewed as vital to the Anglo-Swedish drugmaker's future success
Full story
-
June 30, 2011
New draft guidance from NICE recommends the use of AstraZeneca's anti-platelet drug Brilique (ticagrelor) in combination with aspirin as an option to treat adults with acute coronary syndromes (ACS).
Full story